Is Rituximab a targeted drug?

Rituximab (Rituximab) is a targeted drug that is used to treat certain types of lymphoma or leukemia. During treatment there may be the original rituximab drug Mabthera (Mabthera), or biosimilars such as Truxima, Ruxience or Rixathon. Biosimilars are copies that are very similar to the original drug, but not identical. Rituximab is a targeted cancer drug called a monoclonal antibody. Monoclonal antibodies target proteins on the surface of cancer cells. Rituximab targets a protein called CD20. CD20 is found in white blood cells called B cells. Rituximab works by attaching itself to any CD20 protein it finds. Cells of the immune system then pick out the tagged cells and kill them.

Rituximab has been launched in China and has entered the scope of Class B medical insurance. The use of rituximab must be carried out by doctors and medical staff. It is a strictly controlled drug, and its purchase and use may be restricted. The price of 500mg/500mL per box may be around RMB 8,000, which is relatively expensive. Rituximab has also been launched overseas. The price of the original Indian version of 500mg/500mL per box may be around RMB 3,000 (the price may fluctuate due to exchange rates) . There are also generic rituximab drugs produced by other pharmaceutical companies in India. The price of 500mg/500mL per box may be around 1,500 yuan (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of domestic and foreign original drugs.